Management of Takotsubo Syndrome in a Patient With Pneumonia and Suspected COPD
A 78-year-old woman presenting with a body weight of 32 kg and a 100-pack-year smoking history developed Takotsubo syndrome while being treated for pneumonia and suspected chronic obstructive pulmonary disease, Cureus reported.
Key Clinical Takeaways:
- The patient received a sequential treatment of a transdermal beta-1-blocker followed by an inhaled beta-2-agonist.
- Echocardiography and dual-isotope myocardial scintigraphy confirmed apical akinesis and a perfusion-metabolism mismatch.
- Both therapies were administered without causing a deterioration in cardiac or respiratory status.
Referred to the hospital for worsening dyspnea, the patient was found in a tripod position with a body temperature of 38.9°C, a heart rate of 110 beats per minute, and an oxygen saturation of 89% on room air.
Laboratory tests showed an elevated white blood cell count of 11,800 per microliter and a C-reactive protein level of 15.73 milligrams per deciliter, leading to a diagnosis of pneumonia based on chest radiography and computed tomography findings in the left lower lobe.
Routine electrocardiography unexpectedly revealed ST-segment elevation in leads II, III, aVF, -aVR, and V3 through V5, with a maximum elevation of 2 millimeters in lead V3. Additional blood panels revealed elevated N-terminal pro-B-type natriuretic peptide at 3,476 picograms per millilitre and troponin I at 150.2 picograms per millilitre. Echocardiography subsequently identified a small area of akinesis confined to the apical tip alongside hyperkinesis of the basal segments.
Intravenous ceftriaxone at 2 grams per day was administered for the pneumonia, while transdermal bisoprolol at 2 milligrams per day was initiated to control the patient’s elevated heart rate. On hospital day 8, dual-isotope myocardial scintigraphy using thallium-201 and iodine-123-beta-methyl-p-iodophenyl-pentadecanoic acid demonstrated a marked perfusion-metabolism mismatch in the apical region. Spirometry performed the same day showed an FEV1/FVC ratio of 66 percent, confirming airflow obstruction consistent with chronic obstructive pulmonary disease.
Following the discontinuation of bisoprolol, inhaled olodaterol at 5 micrograms per day was introduced to treat the respiratory symptoms. The patient’s clinical condition remained stable, allowing for discharge on hospital day 12 without recurrent symptoms by post-discharge day 44.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.